RealTalk MS

Past Podcast Episodes

Episode 83: Progressive MS Day with MS Warrior Kevin Reid


March 28th is Progressive MS Day. While only about 15% of the people diagnosed with MS are initially given a diagnosis of Primary Progressive MS, about 65% of the people who are diagnosed with relapsing-remitting MS will eventually develop Secondary Progressive MS. And the difference between progressive MS and relapsing-remitting MS is that, usually, people diagnosed with Progressive MS don't experience any remission in their disease progression. Their MS just seems to worsen more steadily over time.

And while we have more than a dozen approved disease-modifying therapies for relapsing-remitting MS, we have just one approved disease-modifying therapy for progressive MS. So using Progressive MS Day to highlight the need for more research, more treatments, and more attention to be paid to this less popular but more devastating MS sub-type is important.

Kevin Reid

My guest on the podcast is Kevin Reid, who was diagnosed with relapsing-remitting MS in 2002, and is now living with progressive MS. We'll get Kevin's thoughts about Progressive MS Day and hear about his very successful efforts as an MS Warrior.

We're also talking about a stem cell clinical trial aimed at progressive MS (the National MS Society has invested $1 million in this clinical trial), why neurologists don't seem to be following the recommended guidelines for treating older people living with progressive MS, you'll hear about a couple of excellent MS Association of America webinars and podcasts that focus on the impact of MS on families, and a global webcast that's being hosted by the MS International Federation, featuring some of the top progressive MS experts in the world — it's a webcast that you won't want to miss.

We have a lot to talk about! Are you ready for RealTalk MS?!
___________

Progressive MS Day  1:45

MSAA Webinars & Podcasts Focus on Impact of MS on Families  4:31

Neurologists Aren't Following One Particular MS Treatment Guideline  6:10

National MS Society Funds New Clinical Trial Using Individuals' Own Stem Cells to Treat Progressive MS  9:31

In Global Webcast, Top Experts Will Discuss Solving Progressive MS: Progress Achieved and Hope for the Future 11:09

My Interview with Kevin Reid  14:06

Join the RealTalk MS Conversation  27:11

___________

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes.

Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jonstrum@RealTalkMS.com
Phone: (310) 526-2283

___________

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Download the RealTalk MS App for iOS

Download the RealTalk MS App for Android

Give RealTalk MS a Rating & Review

Podcast: Exploring Relationships & MS with Miriam Franco, MSW, PsyD, MSCS

Webinar: Intimacy & Family Planning with MS with Kimberly Castelo, LMFT, CST, CIIP

Webinar: The Partnership of Care: Redefining Caregiver to Care Partner with Megan Weigel, DNP, ARNP-c, MSCN

Podcast: Spotlighting Care Partner Needs with Lara Krawchuk, MSW, LCSW, MPH

___________

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 83
Hosted By: Jon Strum
Guest: Kevin Reid

Tags: MS, MultipleSclerosis, MSResearch, mssociety, ProgressiveMS, MSAssociation, MSIF, CrushMS, Stemcells, RealTalkMS

Episode 82: Minority Participation in MS Clinical Research with Dr. Mitzi Joi Williams


MS is an equal opportunity neurological disease. It doesn't seem to discriminate against any particular ethnic or racial group. It affects Latinos and African-Americans, as well as Caucasians. And if you're an MS research scientist, who's hoping to create a viable treatment that's going to be safe & effective for the diverse population living with multiple sclerosis, then having that diversity represented in your clinical research seems like it would be important. Unfortunately, it doesn't always happen that way. Minority populations are frequently overlooked and under-represented in MS clinical research.

My guest on the podcast is Dr. Mitzi Joi Williams, a neurologist and MS Specialist with a strong interest in better understanding the course of MS in ethnic minority populations, and in increasing diversity in clinical research.

Dr. Mitzi Joi Williams

We're also talking about important MS stem cell research that's being funded by the Department of Defense, the risks associated with stem cell tourism, a new oral Disease Modifying Therapy for relapsing-remitting MS, and a newly-approved prescription medication for treatment-resistant depression.

We have a lot to talk about! Are you ready for RealTalk MS?!
___________

Promising MS Stem Cell Research Funded by Department of Defense  1:33

National MS Society Announces Strategic Partnership with U.S. Department of Veteran Affairs  4:32

The Risks of Stem Cell Tourism 5:26

Celgene Seeks EMA Approval of Ozanimod  11:29

FDA Approves Esketamine for Treatment-Resistant Depression  12:50

My Interview with Dr. Mitzi Joi Williams  16:27

___________

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes.

Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jonstrum@RealTalkMS.com
Phone: (310) 526-2283

___________

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Download the RealTalk MS App for iOS

Download the RealTalk MS App for Android

Give RealTalk MS a Rating & Review

Using Reprogrammed Stem Cells as a Therapy for MS

Complications of Stem Cell Tourism in Multiple Sclerosis & Other Neurological Diseases: Results From First Nationwide Survey of Academic Neurologists

Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

FDA Approves Esketamine Nasal Spray for Treatment of Resistant Depression

MS Made Simple by Dr. Mitzi Joi Williams

___________

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 82
Hosted By: Jon Strum
Guest: Dr. Mitzi Joi Williams

Tags: MS, MultipleSclerosis, MSResearch, mssociety, Ozanimod, Esketamine, iConquerMS, Stemcells, RealTalkMS